Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

34.23
-0.0133-0.04%
Post-market: 34.230.00000.00%16:10 EDT
Volume:4K
Turnover:120.31K
Market Cap:43.64M
PE:- -
High:34.42
Open:34.40
Low:34.10
Close:34.24
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.88
T/O Rate:0.28%
Dividend:0.08
Dividend Rate:0.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

Reuters
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55

Simply Wall St.
·
Aug 27

Ascendis Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Aug 27

Eli Lilly & Co. Stock Slips 3.6%, Underperforms Peers

Dow Jones
·
Aug 27

Moderna Inc. Stock Falls 5.8%, Underperforms Peers

Dow Jones
·
Aug 27

Gilead Sciences Updates Financial Calendar with Investor Conference Presentations

Reuters
·
Aug 27

Sector Update: Healthcare

MT Newswires Live
·
Aug 27

Roche receives FDA approval for companion diagnostic tests for Ziihera

TIPRANKS
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

TIPRANKS
·
Aug 27

Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

TIPRANKS
·
Aug 26

Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

TradingKey
·
Aug 26

Eli Lilly Study Shows Lower Healthcare Costs With Zepbound in Older Adults

MT Newswires Live
·
Aug 26

Zepbound Linked to Lower Healthcare Costs in Adults over Age 55 with Obesity According to a Real-World Study

THOMSON REUTERS
·
Aug 26

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Simply Wall St.
·
Aug 26

Sweden's BioArctic Q2 Revenue Falls Despite Higher Leqembi Royalties

Reuters
·
Aug 26